BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from AML-001, its phase III study of ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is pleased to announce that generic ...

Mylan announced the launch of Azacitidine for Injection, the generic version of Celgene's Vidaza Injection. Vidaza Injection is indicated for the treatment of the five French-American-British (FAB) ...

--First drug approved by FDA for treatment of all MDS risk categories --First drug to achieve a transfusion independence rate of greater than 40 percent across all MDS risk categories --First MDS drug ...

Hikma is introducing azacitidine for injection, in a dosage strength of 100 mg. The product is the generic of Celgene’s Vidaza. It is indicated for treatment of patients with the following ...

The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued ...

Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia. Oral hypomethylating agents (HMAs ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved azacitidine for treatment of pediatric patients with newly diagnosed juvenile myelomonocytic ...

BOULDER, Colo., Aug. 29 -- Pharmion Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oral Azacitidine in the treatment of ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug in a new class of compounds, ...